For acute treatment at 2 hours, 21.2% of patients on Nurtec ODT achieved migraine pain freedom vs 10.9% on placebo; Δ10.3%† (P<.001), and 35.1% achieved freedom from MBS vs 26.8% on placebo; Δ8.3%† (P=.001) (coprimary endpoints). For preventive treatment, patients taking rimegepant 75 mg (n=348) reduced MMDs by 4.3 days vs 3.5 days for those on placebo (n=347) at weeks 9-12 compared with baseline observation period; Δ-0.8† (P=.01).1-3,‡
†Risk difference from placebo based on Cochran-Mantel-Haenszel method.2,3
‡Analyzed using a generalized linear mixed-effects model with treatment group, preventive migraine medication use at randomization, study month, and month-by-treatment group interaction as fixed effects and participant as random effect.2
MBS=most bothersome symptom; MMDs=monthly migraine days.
More than 162,000 providers have written over 6.7 million prescriptions for Nurtec ODT§
The only migraine medication that can provide both rapid relief and powerful prevention1-3
§Per IQVIA XPO report, accessed 5/17/24. Rankings included new prescriptions and renewals.
Most insured adults in the US can get Nurtec ODT
through their health insurance*
Most insured adults in the US can get Nurtec ODT through their health insurance*
With coverage for ~95% of commercially insured lives*
Ellie's migraine story
I know if I get a migraine
attack, I can take my
Nurtec ODT to help me
get back to my normal
activities. I can hang out
with my friends and family.
Ellie W.
Actual Nurtec ODT patient.
Individual results may vary.
Patients were invited to share their experiences on Nurtec ODT. All content was accurate at the time of publication.
References: 1. Nurtec ODT. Package insert. Pfizer Inc. 2. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2020;397(10268): 51-60. doi:10.1016/S0140-6736(20)32544-7 3. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745.